BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 28404946)

  • 21. Long non-coding RNA CTA sensitizes osteosarcoma cells to doxorubicin through inhibition of autophagy.
    Wang Z; Liu Z; Wu S
    Oncotarget; 2017 May; 8(19):31465-31477. PubMed ID: 28415557
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined analysis of DNA methylation and gene expression profiles of osteosarcoma identified several prognosis signatures.
    Tian W; Li Y; Zhang J; Li J; Gao J
    Gene; 2018 Apr; 650():7-14. PubMed ID: 29407229
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High-dose chemotherapy with stem cell rescue in the primary treatment of metastatic and pelvic osteosarcoma: final results of the ISG/SSG II study.
    Boye K; Del Prever AB; Eriksson M; Saeter G; Tienghi A; Lindholm P; Fagioli F; Skjeldal S; Ferrari S; Hall KS
    Pediatr Blood Cancer; 2014 May; 61(5):840-5. PubMed ID: 24254749
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma: a pilot study.
    Windsor RE; Strauss SJ; Kallis C; Wood NE; Whelan JS
    Cancer; 2012 Apr; 118(7):1856-67. PubMed ID: 21887680
    [TBL] [Abstract][Full Text] [Related]  

  • 25. pFAK-Y397 overexpression as both a prognostic and a predictive biomarker for patients with metastatic osteosarcoma.
    Thanapprapasr K; Nartthanarung A; Thanapprapasr D; Jinawath A
    PLoS One; 2017; 12(8):e0182989. PubMed ID: 28846700
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mediator of RNA polymerase II transcription subunit 19 promotes osteosarcoma growth and metastasis and associates with prognosis.
    Yu W; Zhang Z; Min D; Yang Q; Du X; Tang L; Lin F; Sun Y; Zhao H; Zheng S; He A; Li H; Yao Y; Shen Z
    Eur J Cancer; 2014 Apr; 50(6):1125-36. PubMed ID: 24565852
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of metastatic osteosarcoma at diagnosis: a Pediatric Oncology Group Study.
    Harris MB; Gieser P; Goorin AM; Ayala A; Shochat SJ; Ferguson WS; Holbrook T; Link MP
    J Clin Oncol; 1998 Nov; 16(11):3641-8. PubMed ID: 9817286
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MicroRNA-187 Inhibits Growth and Metastasis of Osteosarcoma by Downregulating S100A4.
    Xiao Y; Zhao Q; Du B; Chen HY; Zhou DZ
    Cancer Invest; 2018 Jan; 36(1):1-9. PubMed ID: 29303365
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nonmetastatic osteosarcoma of the extremity. Neoadjuvant chemotherapy with methotrexate, cisplatin, doxorubicin and ifosfamide. An Italian Sarcoma Group study (ISG/OS-Oss).
    Ferrari S; Meazza C; Palmerini E; Tamburini A; Fagioli F; Cozza R; Ferraresi V; Bisogno G; Mascarin M; Cefalo G; Manfrini M; Capanna R; Biagini R; Donati D; Picci P
    Tumori; 2014; 100(6):612-9. PubMed ID: 25688494
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A long non-coding RNA contributes to doxorubicin resistance of osteosarcoma.
    Zhang CL; Zhu KP; Shen GQ; Zhu ZS
    Tumour Biol; 2016 Feb; 37(2):2737-48. PubMed ID: 26408180
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dysregulation of macrophage polarization is associated with the metastatic process in osteosarcoma.
    Dumars C; Ngyuen JM; Gaultier A; Lanel R; Corradini N; Gouin F; Heymann D; Heymann MF
    Oncotarget; 2016 Nov; 7(48):78343-78354. PubMed ID: 27823976
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increased expression of lncRNA HULC indicates a poor prognosis and promotes cell metastasis in osteosarcoma.
    Sun XH; Yang LB; Geng XL; Wang R; Zhang ZC
    Int J Clin Exp Pathol; 2015; 8(3):2994-3000. PubMed ID: 26045809
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group.
    Meyers PA; Schwartz CL; Krailo MD; Healey JH; Bernstein ML; Betcher D; Ferguson WS; Gebhardt MC; Goorin AM; Harris M; Kleinerman E; Link MP; Nadel H; Nieder M; Siegal GP; Weiner MA; Wells RJ; Womer RB; Grier HE;
    J Clin Oncol; 2008 Feb; 26(4):633-8. PubMed ID: 18235123
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients.
    Caronia D; Patiño-García A; Milne RL; Zalacain-Díez M; Pita G; Alonso MR; Moreno LT; Sierrasesumaga-Ariznabarreta L; Benítez J; González-Neira A
    Pharmacogenomics J; 2009 Oct; 9(5):347-53. PubMed ID: 19434073
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis of chemotherapy dosage and dosage intensity and survival outcomes of high-grade osteosarcoma patients younger than 40 years.
    Sun L; Li Y; Li H; Zhang J; Li B; Ye Z
    Clin Ther; 2014 Apr; 36(4):567-78. PubMed ID: 24636527
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metastatic osteosarcoma at diagnosis: prognostic factors and long-term outcome--the French pediatric experience.
    Mialou V; Philip T; Kalifa C; Perol D; Gentet JC; Marec-Berard P; Pacquement H; Chastagner P; Defaschelles AS; Hartmann O
    Cancer; 2005 Sep; 104(5):1100-9. PubMed ID: 16015627
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Osteosarcoma recurrences in pediatric patients previously treated with intensive chemotherapy.
    Tabone MD; Kalifa C; Rodary C; Raquin M; Valteau-Couanet D; Lemerle J
    J Clin Oncol; 1994 Dec; 12(12):2614-20. PubMed ID: 7989936
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression profiles of osteosarcoma that can predict response to chemotherapy.
    Man TK; Chintagumpala M; Visvanathan J; Shen J; Perlaky L; Hicks J; Johnson M; Davino N; Murray J; Helman L; Meyer W; Triche T; Wong KK; Lau CC
    Cancer Res; 2005 Sep; 65(18):8142-50. PubMed ID: 16166288
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinicopathologic significance of S100A4 expression in osteosarcoma.
    Cao CM; Yang FX; Wang PL; Yang QX; Sun XR
    Eur Rev Med Pharmacol Sci; 2014; 18(6):833-9. PubMed ID: 24706307
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Candidate germline polymorphisms of genes belonging to the pathways of four drugs used in osteosarcoma standard chemotherapy associated with risk, survival and toxicity in non-metastatic high-grade osteosarcoma.
    Hattinger CM; Biason P; Iacoboni E; Gagno S; Fanelli M; Tavanti E; Vella S; Ferrari S; Roli A; Roncato R; Giodini L; Scotlandi K; Picci P; Toffoli G; Serra M
    Oncotarget; 2016 Sep; 7(38):61970-61987. PubMed ID: 27566557
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.